US drugmaker Regeneron has agreed to purchase genetics testing start-up 23andMe out of bankruptcy for $256 million, following the company’s decline in market value from $5.8 billion in 2021, amid concerns over its unprofitable business model and data privacy issues. Co-founder Anne Wojcicki will relinquish control as part of the sale, which aims to maintain customer privacy policies while allowing Regeneron to continue offering 23andMe’s genetic testing services. The acquisition raises concerns among the 15 million users about the potential use of their genetic data by a pharmaceutical company.